Quoin Pharmaceuticals, Ltd. is a clinical-stage specialty pharma company focused on rare diseases, notably Netherton Syndrome through its lead candidate QRX003. The company’s progress includes orphan drug designations in multiple jurisdictions and initiation of Phase 3 pivotal trials following FDA clearance in 2026. However, sustained operating losses exceeding $15 million in FY2025 and constraints on capital raising highlight substantial liquidity risks. Intellectual property protections through its Invisicare® technology bolster its moat, but continued clinical and regulatory success is essential to realize value.